MMSI

Business Context and Reporting Period

Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2010
Business Overview: Merit Medical designs, manufactures, and markets medical devices for cardiovascular and endoscopy procedures. The company operates two reportable segments: Cardiovascular and Endoscopy.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10% in the quarter and 13% for the nine-month period compared to 2009. Growth was driven by the Cardiovascular segment (up 11% and 13% respectively), specifically due to the EN Snare device and the recent acquisition of BioSphere. The Endoscopy segment sales declined 22% in the quarter due to sales force turnover and elimination of certain procedures.
• Profitability Decline: Net income decreased 53% for the nine-month period. The third quarter resulted in a net loss of $2.0 million compared to a profit of $6.1 million in the prior year.
• Goodwill Impairment: A non-cash goodwill impairment charge of $8.3 million was recorded in the third quarter related to the Endoscopy reporting unit. This charge was the primary driver of the operating loss for the quarter.
• Acquisition Activity: On September 10, 2010, the company acquired BioSphere Medical, Inc. for approximately $96 million in cash. This transaction significantly increased inventory, receivables, and intangible assets on the balance sheet.
• Debt Financing: To fund the BioSphere acquisition, the company entered into a new $125 million revolving credit facility with Wells Fargo, replacing a previous line of credit with Bank of America. Outstanding borrowings under the new facility were approximately $88 million as of period end.

Guidance, Outlook, and Risks

• Management Commentary: Management attributes the decline in net income primarily to the $8.3 million goodwill impairment, acquisition-related costs ($2.3 million for the nine months), and severance costs ($1.6 million). Excluding these items, operating income would have been higher.
• Future Investments: The company plans to construct two new production facilities in South Jordan, Utah, and Galway, Ireland, with an anticipated cost of $52 million over the next two years.
• Market Expansion: The company began direct shipments in China in September 2010, terminating a previous distribution agreement to improve margins and sales control. They are also seeking additional regulatory licenses in China.
• Risks and Contingencies:
  • Integration Risk: Risks associated with integrating the BioSphere acquisition and managing growth.
  • Regulatory Risk: Delays in obtaining regulatory approvals for new products.
  • Market Risk: Exposure to foreign currency fluctuations (Euro, GBP) and interest rate changes on floating-rate debt (partially mitigated by a $55 million interest rate swap entered into in October 2010).
  • Goodwill Impairment: Continued operating losses and slower sales growth in the Endoscopy segment pose a risk of future impairments.

Investor Verification Checklist

• Goodwill Impairment Validity: Verify the assumptions used in the discounted cash flow analysis for the Endoscopy segment that led to the $8.3 million impairment charge.
• BioSphere Integration: Monitor the realization of synergies and the performance of the acquired embolotherapy products in the coming quarters.
• Debt Covenants: Confirm continued compliance with the new Credit Agreement covenants, specifically the Consolidated Total Leverage Ratio (max 2.5 to 1 through June 2012).
• Endoscopy Segment Turnaround: Assess whether the decline in Endoscopy sales is temporary or indicative of a structural market shift.
• Capital Expenditures: Track the $52 million planned spend on new facilities and its impact on future cash flows.